BACKGROUND:Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in patients with breast cancer. METHODS:Twelve women (42-71 years) with breast cancer were randomly assigned to a 3-hour imaging protocol with peritumoral/subdermal injections (.5 mCi) of either Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m) or.2 micro m of fTcSC. Serial images were acquired for 180 minutes. Sentinel nodes, excised within 4.2 to 7.3 hours of administration, were assayed in a dose calibrator. RESULTS: The receptor-binding agent, Lymphoseek, exhibited a significantly (P =.0025) faster injection site clearance (rate,.255 +/-.147/hour; fTcSC rate,.014 +/-.018/hour); the mean Lymphoseek clearance half-time was 2.72 +/- 1.57 hours compared with 49.5 +/- 38.5 hours for fTcSC. The primary sentinel node uptake of Lymphoseek (range,.02%-1.12%; mean,.55% +/-.43%) and fTcSC (range,.00%-1.93%; mean,.65% +/-.63%) did not differ (P =.75). Lymphoseek exhibited a lower mean number of sentinel nodes per study (n = 1.3) than fTcSC (n = 1.7) and a higher concordance with Lymphazurin. CONCLUSIONS: The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC.
RCT Entities:
BACKGROUND:Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in patients with breast cancer. METHODS: Twelve women (42-71 years) with breast cancer were randomly assigned to a 3-hour imaging protocol with peritumoral/subdermal injections (.5 mCi) of either Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m) or.2 micro m of fTcSC. Serial images were acquired for 180 minutes. Sentinel nodes, excised within 4.2 to 7.3 hours of administration, were assayed in a dose calibrator. RESULTS: The receptor-binding agent, Lymphoseek, exhibited a significantly (P =.0025) faster injection site clearance (rate,.255 +/-.147/hour; fTcSC rate,.014 +/-.018/hour); the mean Lymphoseek clearance half-time was 2.72 +/- 1.57 hours compared with 49.5 +/- 38.5 hours for fTcSC. The primary sentinel node uptake of Lymphoseek (range,.02%-1.12%; mean,.55% +/-.43%) and fTcSC (range,.00%-1.93%; mean,.65% +/-.63%) did not differ (P =.75). Lymphoseek exhibited a lower mean number of sentinel nodes per study (n = 1.3) than fTcSC (n = 1.7) and a higher concordance with Lymphazurin. CONCLUSIONS: The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC.
Authors: Sean P Stroup; Christopher J Kane; Salman Farchshchi-Heydari; Claude M James; Christopher H Davis; Anne M Wallace; Carl K Hoh; David R Vera Journal: Clin Exp Metastasis Date: 2012-06-20 Impact factor: 5.150
Authors: Christopher A Tokin; Frederick O Cope; Wendy L Metz; Michael S Blue; Beth M Potter; Bonnie C Abbruzzese; Richard D Hartman; Marcus T Joy; Dennis W King; Lori A Christman; David R Vera; Anne M Wallace Journal: Clin Exp Metastasis Date: 2012-06-23 Impact factor: 5.150
Authors: Ruchi Sharma; Juliet A Wendt; John C Rasmussen; Kristen E Adams; Milton V Marshall; Eva M Sevick-Muraca Journal: Ann N Y Acad Sci Date: 2008 Impact factor: 5.691
Authors: Frederick O Cope; Bonnie Abbruzzese; James Sanders; Wendy Metz; Kristyn Sturms; David Ralph; Michael Blue; Jane Zhang; Paige Bracci; Wiam Bshara; Spencer Behr; Toby Maurer; Kenneth Williams; Joshua Walker; Allison Beverly; Brooke Blay; Anirudh Damughatla; Mark Larsen; Courtney Mountain; Erin Neylon; Kaeli Parcel; Kapil Raghuraman; Kevin Ricks; Lucas Rose; Akhilesh Sivakumar; Nicholas Streck; Bryan Wang; Christopher Wasco; Larry S Schlesinger; Abul Azad; Murugesan V S Rajaram; Wael Jarjour; Nicholas Young; Thomas Rosol; Amifred Williams; Michael McGrath Journal: Nucl Med Biol Date: 2015-12-03 Impact factor: 2.408
Authors: Zhengtao Qin; David J Hall; Michael A Liss; Carl K Hoh; Christopher J Kane; Anne M Wallace; David R Vera Journal: J Biomed Opt Date: 2013-10 Impact factor: 3.170
Authors: Hop S Tran Cao; Michele McElroy; Sharmeela Kaushal; Robert M Hoffman; Michael Bouvet Journal: Adv Drug Deliv Rev Date: 2011-06-28 Impact factor: 15.470